Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.48−0.22 (-4.68%)
Close on Nov 18, 2026Market cap $277.06MP/E –Yield –
Kyverna Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kyverna Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$150.80M. For fiscal 2025 it was -$153.71M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$153.71M | – |
| FY2024 | Dec 31, 2024 | -$114.25M | – |
| FY2023 | Dec 31, 2023 | -$52.41M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$35.37M | – |
| Q2 FY2026 | Jun 30, 2026 | -$40.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$33.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$43.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.49M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.53M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.46M | – |
See a number that looks wrong?